Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 5

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 5
---
 “Enforceability of Civil Liabilities”
for additional information.

In this prospectus, “we,” “us,”
“our,” the “Company” and “NLS” refer to NLS Pharmaceutics Ltd., and its wholly owned subsidiary, NLS
Pharmaceutics Inc., a Delaware corporation.

Our reporting currency and functional currency
is the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus to “dollars,”
“USD” or “$” mean U.S. dollars, and references to “CHF” are to the Swiss Franc. U.S. dollar translations
of CHF amounts presented in this prospectus were done on different dates in accordance with the date as of such entry in the Company’s
books and are derived from our audited financial statements incorporated by reference in this prospectus. U.S. dollar translations of
CHF amounts presented in this prospectus that are not derived from our audited financial statements incorporated by reference in this
prospectus are translated using the rate of CHF 1.00 to $1.1034, based on the exchange rate provided by the Swiss Federal Tax Administration
on December 31, 2024.

All information included herein relating to shares
or price per share reflects the 1-for-40 reverse split effected by us on September 27, 2024. Further, on January 14, 2025, the shareholders
of the Company approved a change in the par value of our Common Shares from CHF 0.80 to CHF 0.03 per share, effective January 17, 2025.

<div align='center'>ii

OUR COMPANY</div>

The Company

We are a clinical-stage biopharmaceutical company
focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders
with unmet medical needs. Our lead compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in
a proprietary extended-release, or ER, formulation, is being developed for the treatment of narcolepsy (lead indication) and attention
deficit hyperactivity disorder, or ADHD (follow-on indication). We believe that this dual mechanism of action will also enable mazindol
ER to provide potential therapeutic benefit in other rare and complex CNS disorders. CNS disorders are a diverse group of conditions that
include neurological, psychiatric, and substance use